Methods of treating cognitive impairment

Patent metadata

Field	Value
Publication number	US-11896647-B2
Application number	US-202016938736-A
Country	US
Kind code	B2
Filing date	Jul 24, 2020
Priority date	Aug 5, 2008
Publication date	Feb 13, 2024
Grant date	Feb 13, 2024

Abstract

The subject invention concerns materials and methods for treating a person or animal having cognitive impairment. In one embodiment, the method comprises administering an effective amount of one or more inflammatory mediator(s), for example, fms-related tyrosine kinase 3 (Flt3) ligand, interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF), interleukin-1 (IL-1), interleukin-3 (IL-3), erythropoietin (EPO), vascular endothelial growth factor A (VEGF-A), hypoxia-inducible transcription factor (HIF-1alpha), insulin like growth factor-1 (IGF-1), tumor necrosis factor (TNF), granulocyte colony-stimulating factor (G-CSF), granulocyte/macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF), Stem Cell Factor (SCF), Darbepoetin (ARANESP), and metalloproteinases, to an animal or person in need of treatment.

First claim

We claim:

1. A method for reducing the level of an amyloid beta (Aβ) peptide in the brain of a person or animal, comprising administering to the person or animal an effective amount of a granulocyte/macrophage colony-stimulating factor (GM-CSF) or sargramostim, or a composition comprising GM-CSF or sargramostim, wherein the level of an AP peptide is reduced in the person or animal relative to the level of AP peptide in the brain of the person or animal prior to administration of the GM-CSF.

2. The method according to claim 1 , wherein said GM-CSF is human GM-CSF.

3. The method according to claim 1 , wherein said GM-CSF comprises the amino acid sequence of SEQ ID NO: 1, or said GM-CSF has greater than 90% sequence identity with the amino acid sequence of SEQ ID NO: 1.

4. The method of claim 1 , wherein administering comprises administration of GM-CSF or sargramostim at a dose of about 0.028 mg/kg of bodyweight of the person or animal.

5. The method of claim 1 , wherein the amyloid beta (Aβ) peptide comprises deposited amyloid beta.

6. A method for increasing the synaptic density in the CA1 or CA3 regions of the hippocampus of a person with Alzheimer's disease, comprising administering to the person an effective amount of a granulocyte/macrophage colony-stimulating factor (GM-CSF) or sargramostim, or a composition comprising GM-CSF or sargramostim, whereby the person exhibits increased synaptic density relative to the level of synaptic density in the CA1 or CA3 regions of the hippocampus of the person prior to administration of GM-CSF.

7. The method of claim 6 , wherein administering comprises administration of GM-CSF or sargramostim at a dose of about 0.028 mg/kg of bodyweight of the person with Alzheimer's disease.

Assignees

• Univ South Florida

Inventors

• Potter Huntington
• Arendash Gary W
• Bennett Steven
• Boyd Timothy

Classifications

• A61K38/193 Primary

  Colony stimulating factors [CSF] · CPC title

• A61K38/1709

  from mammals · CPC title

• A61K38/1816

  Erythropoietin [EPO] · CPC title

• A61K2300/00

  Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00 · CPC title

• A61K38/19 Primary

  Cytokines; Lymphokines; Interferons · CPC title